Safety of adjuvant dose-dense chemotherapy with paclitaxel and epirubicin for high-risk breast cancer / 中华肿瘤杂志
Chinese Journal of Oncology
;
(12): 548-551, 2008.
Article
in Chinese
| WPRIM
| ID: wpr-357376
ABSTRACT
<p><b>OBJECTIVE</b>To investigate the safety and tolerance of adjuvant dose-dense chemotherapy with paclitaxel and epirubicin for high-risk breast cancer.</p><p><b>METHODS</b>From January 2004 to December 2006, 101 patients with high-risk breast cancer after surgical resection were enrolled into this study. The patients were divided into two groups dose-dense and regular groups. Each patient received 6 cycles of chemotherapy with intravenous administration of paclitaxel (175 mg/m2, on D3) and epirubicin (60 mg/m2, on Dl and D2). The dose-dense group had repeated treatment every two weeks, while the regular group repeated it every three weeks. G-CSF was used in a dose of 3 microg/kg on D5-D9 during each cycle in the dose-dense group. While in the regular group, it was used only under the condition that grade II neutropenia occurred.</p><p><b>RESULTS</b>The toxicity could be evaluated in 101 patients. Major grade II-IV toxicities included neutropenia, nausea, vomiting and alopecia. The incidence of grade III-IV neutropenia was 16.0% in the dose-dense group versus 54.9% in the regular group (P = 0.000); postponing of chemotherapy was 2.4% versus 6.0% (P = 0.027). Ninety-eight patients completed the chemotherapy as planed. After a median follow-up of 24 months, the median DFS and OS were not reached. The relapse-free rate and survival rate were 89.8% and 100% in the dose-dense group, which were 87.8% and 93.9% in the regular group. The relapse-free rate of the high-risk patients in the dose-dense group was 86.8% versus 81.3% in the regular group, and the corresponding survival rate was 100% versus 90.6%.</p><p><b>CONCLUSION</b>Adjuvant dose-dense chemotherapy with paclitaxel and epirubicin is safe, tolerable and promising for high-risk breast cancer.</p>
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Pathology
/
General Surgery
/
Vomiting
/
Breast Neoplasms
/
Epirubicin
/
Antineoplastic Combined Chemotherapy Protocols
/
Survival Rate
/
Follow-Up Studies
/
Granulocyte Colony-Stimulating Factor
/
Chemotherapy, Adjuvant
Type of study:
Etiology study
/
Observational study
/
Prognostic study
/
Risk factors
Limits:
Adult
/
Female
/
Humans
Language:
Chinese
Journal:
Chinese Journal of Oncology
Year:
2008
Type:
Article
Similar
MEDLINE
...
LILACS
LIS